GU ASCO annual meeting featured a urothelial carcinoma session and a discussant presentation by Dr. Scot Niglio discussing two abstracts: “Safety and efficacy of neoadjuvant immunotherapy with ...

Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Toichi Takino; “Ono”) announced that the U.S. Food and Drug Administration (FDA) ...

Results from the company’s Talapro-2 trial saw a 38% reduction in the risk of death among HRR-mutated patients.

Vistagen Therapeutics, Inc.'s fasedienol shows promise in treating social anxiety; new results expected 2025. Click for my ...

Positve overall survival data could lead to a label expansion for Pfizer's combination to treat metastatic ...

General and Administration (G&A) expenses for the three months ended December 31, 2024 were $3.6 million USD, compared to $5.3 million USD for the same period in 2023. The decrease was primarily ...

Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 billion of non-cash charges related to manufacturing resizing ...

Q3 2025 Management View CEO Shawn Singh outlined the company’s progress on its lead clinical programs, particularly fasedienol, which is being developed for the acute treatment of social anxiety ...

The primary endpoint is objective response rate, with progression-free survival a key secondary endpoint. The study includes a pre-registration step for arm determination by the molecular tumor board.

Allogene Therapeutics (ALLO) announced the publication of data from its Phase 1 ALPHA and ALPHA2 clinical studies of cemacabtagene ...

Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates ...

Faricimab demonstrated noninferior vision gains and improved anatomical outcomes among patients with diabetic macular edema ...